Condition

Targeted Therapy clinical trials and research

• 14Clinical trials
• 104NIH research projects
• 3Countries

Newest Targeted Therapy clinical trials

All recruiting trials (14)

• Emotional health and outcomes for advanced liver cancer patients receiving HAIC plus targeted therapy and immunotherapy

  We will see if baseline emotional status (depressive versus non‑depressive) changes treatment outcomes in adults with BCLC stage B/C hepatocellular carcinoma getting hepatic arterial infusion chemotherapy combined with targeted therapy and immunotherapy.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07436845

• HLA-G-targeted exosome SOB100 in healthy adults

  This trial will test whether a new HLA-G-targeted exosome called SOB100 is safe and how it behaves in the body when given to healthy adults.

  Recruiting Phase 1 Shine-On Biomedical Co., Ltd. · Baltimore, Maryland · NCT07219940

• Short-course pelvic radiotherapy followed by CAPOX (capecitabine + oxaliplatin) and bevacizumab, with or without PD‑1 immunotherapy, for locally advanced rectal cancer.

  This trial tests whether adding a PD‑1 immunotherapy to short-course radiotherapy followed by CAPOX and bevacizumab helps adults with locally advanced rectal cancer get a higher complete response rate and fewer distant metastases.

  Recruiting Phase 2 Ruijin Hospital · Shanghai · NCT07198165

• Olutasidenib combined with targeted agents for relapsed IDH1‑mutated myeloid cancers with activated signaling mutations

  This trial tests whether adding olutasidenib to targeted drugs or low‑intensity chemotherapy helps adults with relapsed or refractory IDH1‑mutated myeloid malignancies that also have an activated signaling mutation.

  Recruiting at 2 sites Phase 2 M.D. Anderson Cancer Center · Miami, Florida and 1 other locations · NCT07032727

• Combining radiation therapy with targeted and immunotherapy for advanced kidney cancer

  This study is testing a new treatment that combines radiation therapy with two other medications to see if it helps people with advanced kidney cancer live longer without their disease getting worse.

  Recruiting Phase 2 Peking University First Hospital · Beijing, Beijing Municipality · NCT06889649

• Oral trifluridine/tipiracil with bevacizumab and sintilimab, with or without targeted radiation, for advanced MSS/pMMR colorectal cancer after two or more prior treatments

  This trial will try oral trifluridine/tipiracil combined with bevacizumab and sintilimab, with or without focused radiation, in people with advanced MSS/pMMR colorectal cancer who have progressed after at least two prior therapies.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06764680

• Observational study on managing blood-related side effects in breast cancer targeted therapies

  This study looks at how to manage blood-related side effects in breast cancer patients receiving targeted therapies to see what works best for them.

  Recruiting Fudan University · Shanghai, Not US/Canada · NCT06503380

• Combining Fruquintinib, Regorafenib, and Sintilimab with Radiotherapy for Advanced Colorectal Cancer

  This study is testing a new combination of three cancer drugs with or without radiation to see if it helps people with advanced colorectal cancer who have already tried other treatments.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06356584

• Combining targeted therapies for solid tumors using CDK4/6 inhibitors and anti-VEGF agents

  This study is testing if combining two cancer treatments, Palbociclib and Bevacizumab, can help people with solid tumors like colorectal, breast, and ovarian cancers feel better and respond better to treatment.

  Recruiting at 2 sites Phase 1 Lebanese University · Tripoli, North Lebanon and 1 other locations · NCT06307249

• Evaluating targeted therapy effectiveness in advanced lung cancer using RecistTM criteria

  This study is testing if a new way to measure how well targeted therapy works can help people with advanced lung cancer who have specific gene changes.

  Recruiting Third Military Medical University · Chongqing, Chongqing Municipality · NCT06142058

• Combining chidamide and everolimus for advanced breast cancer treatment

  This study is testing whether combining a new drug called chidamide with hormone therapy helps people with a specific type of advanced breast cancer, while also seeing if everolimus works better for those with a different gene mutation.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT05983107

• Supportive care model for patients with advanced lung cancer

  This study is testing a new supportive care program for people with advanced lung cancer to see if it helps them feel less stressed and more confident about managing their condition compared to standard care.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT04900935

• Neoadjuvant treatments for esophageal cancer

  This study is testing different combinations of treatments for people with esophageal cancer to see if they can improve outcomes compared to just having surgery.

  Recruiting Phase 3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT04821843

• Chemoradiotherapy for esophageal and esophagogastric junction cancer

  This study is testing a new combination of chemotherapy, radiation, and immune therapies to see if it helps people with advanced esophageal or esophagogastric junction cancer live longer and feel better.

  Recruiting at 5 sites Phase 3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Anyang, Henan and 4 other locations · NCT04821778

NIH-funded research (newest 40 of 104)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Integrative histo-genomic analysis to guide cancer risk and targeted therapies with interpretable AI

  Researchers are developing an advanced AI-powered approach to map genetic and cellular patterns across breast and cervical cancers to help tailor treatments.

  NIH research Tuskegee University · Tuskegee Institute, United States · NIH-11621787

• Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response

  Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11611081

• Adipome biomarkers in obese TNBC mice for targeted therapy

  A study in mice explores how fat-derived particles called adipomes influence an aggressive breast cancer type, with the goal of guiding personalized therapies.

  NIH research Hackensack University Medical Center · Hackensack, United States · NIH-11457952

• Enhancing HER2-targeted therapy for resistant breast cancer

  This grant explores new ways to overcome resistance to HER2-targeted therapy in people with HER2-positive breast cancer.

  NIH research Lsu Health Sciences Center · New Orleans, United States · NIH-11457632

• Metabolic imaging to guide targeted therapy for liver cancer

  A clinician-scientist at UPenn is pursuing training to use metabolic imaging to tailor therapy for hepatocellular carcinoma.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11451904

• Targeted therapy for splicing-factor mutant myeloid cancers

  Aims to test a dual drug strategy targeting ATR and PARP pathways in adults with splicing-factor mutant acute myeloid leukemia or related myeloid diseases.

  NIH research Washington University · Saint Louis, United States · NIH-11423682

• TIME-based immunograms to guide sequential cancer immunotherapy

  A patient-friendly look at a research project that tests whether timing and sequencing of immunotherapy with targeted drugs can improve outcomes for people with melanoma and other cancers.

  NIH research Institute for Systems Biology · Seattle, United States · NIH-11415804

• Genomic clues to guide therapy in advanced prostate cancer

  This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11411372

• Integrating targeted therapy and immunotherapy to fight breast cancer

  A cancer research program aims to combine targeted drugs with immunotherapy to improve treatment for breast cancer and brain metastasis.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11400994

• Overcoming Resistance to Targeted Therapy in Breast Cancer

  Researchers are studying why some breast cancers stop responding to targeted therapies and what can be done to overcome this resistance.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11396553

• Understanding how lung cancer changes to resist targeted therapy

  Researchers are studying why a common lung cancer drug stops working and how to block those changes to help patients keep benefiting from treatment.

  NIH research Roswell Park Cancer Institute Corp · Buffalo, United States · NIH-11390505

• Impact of Targeted Cancer Therapy on Thinking and Memory

  This research looks at how targeted cancer drugs (TKIs) affect thinking and memory in patients starting treatment for certain blood cancers.

  NIH research H. Lee Moffitt Cancer Ctr & Res Inst · Tampa, United States · NIH-11381063

• Protein C system in trauma-related blood-clotting and inflammation

  A study aiming to understand how the protein C system affects blood clotting and inflammation after severe injuries and to explore targeted therapies for trauma patients.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-11380019

• Targeted therapy to treat ovarian cancer by promoting cancer cell death

  A new, targeted therapy called EC359 aims to kill ovarian cancer cells and cancer stem cells, potentially improving outcomes for patients who have recurrent, treatment-resistant disease.

  NIH research University of Texas Hlth Science Center · San Antonio, United States · NIH-11374535

• Restore brain-gut balance in kids through targeted therapy

  A child-focused research project is testing a targeted approach to fix autonomic brain-gut signals in young people with gut-brain problems.

  NIH research Medical College of Wisconsin · Milwaukee, United States · NIH-11360673

• Combination therapy targeting tumor and surrounding stroma in pancreatic cancer

  Aims to improve treatment for pancreatic cancer by delivering a targeted therapy together with a agent that changes the tumor environment to help drugs work better.

  NIH research St. John's University · Queens, United States · NIH-11355568

• Imaging and blood DNA testing to track cancer treatment response

  A study tests a blood test and scans together to see if they can better tell when a cancer treatment is working or when it’s stopping working.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11349729

• Enhanced targeted therapy for colorectal cancer in patients with advanced disease

  A new combination approach is being tested to help people with colorectal cancer that has spread, using targeted cancer drugs together with a drug that blocks a key building block the cancer needs.

  NIH research Roswell Park Cancer Institute Corp · Buffalo, United States · NIH-11349033

• Advancing RAS-targeted therapy in NF1-associated nerve tumor – SHP2 and CDK4/6 inhibitors

  This grant explores new drug combinations to treat malignant peripheral nerve sheath tumors (MPNST) in patients with NF1-related cancer by testing SHP2 and CDK4/6 inhibitors and how they affect tumors and surrounding immune cells.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11332584

• PARP1 and targeted treatment for myelodysplastic syndromes

  This work tests whether blocking a protein called PARP1 can help people with myelodysplastic syndromes who have certain RNA splicing gene mutations.

  NIH research University of Minnesota · Minneapolis, United States · NIH-11325793

• New targeted treatment for relapsed multiple myeloma

  A new drug called KS100 aims to block ALDH enzymes to kill treatment-resistant myeloma cells in people whose disease has returned.

  NIH research Rowan University · Glassboro, United States · NIH-11324662

• PET scans to track glutamine use in triple-negative breast cancer

  This project uses special PET scans with an amino-acid tracer to see how triple-negative breast cancers use glutamine so doctors can better match metabolism-targeted treatments to patients.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11324557

• Targeted therapy to reduce health disparities in pediatric leukemia

  A pediatric leukemial therapy study focused on Hispanic/Latino children to improve outcomes by addressing genetic factors that make their leukemia harder to treat.

  NIH research Pennsylvania State Univ Hershey Med Ctr · Hershey, United States · NIH-11324192

• Understanding how the CD24 helper molecule affects early lung cancer and response to KRAS therapies

  A study aims to learn how the CD24 molecule on lung cells influences early lung cancer development, how cancer cells escape the immune system, and how KRAS-targeted therapies might work better when CD24 is involved.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11317439

• ARIH1 inhibitors as a new targeted therapy for triple-negative breast cancer

  Researchers are testing ARIH1 inhibitors to help treat triple-negative breast cancer by making cancer cells more sensitive to chemotherapy and less able to spread.

  NIH research Toomer Therapeutics, INC. · Mount Pleasant, United States · NIH-11312958

• Bivalent CD47 Immunotoxin for Targeted Therapy of T-ALL in kids

  A new targeted therapy using a two-part CD47-directed toxin is being studied for children with T-cell acute lymphoblastic leukemia who have limited treatment options.

  NIH research Rock Immune, INC. · Denver, United States · NIH-11310680

• Targeted treatment to repair and strengthen aortic aneurysms

  A nanoparticle therapy that homes to damaged aortic tissue and delivers a natural compound to rebuild and stabilize the artery wall is being developed for people with abdominal aortic aneurysms to try to stop growth and rupture.

  NIH research Clemson University · Clemson, United States · NIH-11309164

• Targeted treatment for adults with t(8;21) AML (AML1-ETO)

  This project tests drugs that block proteins AML1-ETO needs to grow, aimed at adults with t(8;21) acute myeloid leukemia.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11303330

• Fluorescent-guided laparoscopy with light-activated chemotherapy for tiny ovarian cancer spread

  This uses a fluorescent agent to make tiny ovarian cancer nodules glow during laparoscopy and a near-infrared light to trigger local release of chemotherapy at those spots for people with advanced epithelial ovarian cancer.

  NIH research State University New York Stony Brook · Stony Brook, United States · NIH-11296928

• Understanding SYNCRIP’s role in prostate cancer resistance to AR-targeted therapy

  A study at Yale is looking at how loss of SYNCRIP makes prostate cancer less responsive to common AR-targeted treatments and what this could mean for new ways to treat resistant cancer.

  NIH research Yale University · New Haven, United States · NIH-11292540

• Making HDAC6-targeted treatments work better for breast cancer

  This work looks at how blocking HDAC6 affects breast cancers and finds which patients are most likely to benefit.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11284009

• PLK1 blocker plus HER-targeted therapy to tackle resistance in head and neck cancer

  A study at Yale is exploring a new combination treatment to overcome resistance to EGFR-targeted therapy in head and neck cancer, using a PLK1 inhibitor with a pan-HER blocker.

  NIH research Yale University · New Haven, United States · NIH-11265318

• Targeting gene switches that drive spread in head and neck cancer

  Researchers are testing whether blocking specific epigenetic controls can reduce invasive and metastatic behavior in people with head and neck squamous cell carcinoma.

  NIH research Washington University · Saint Louis, United States · NIH-11250979

• PSCA-targeted antibody for imaging and treating pancreatic cancer

  A specially engineered antibody is used to find and deliver targeted radiation to pancreatic tumors that have high PSCA levels.

  NIH research Beckman Research Institute/city of Hope · Duarte, United States · NIH-11250064

• ASPH-targeted treatment for chondrosarcoma

  A new treatment that targets the ASPH protein is being developed for adults with chondrosarcoma.

  NIH research Rhode Island Hospital · Providence, United States · NIH-11224056

• Understanding how SYNCRIP affects prostate cancer treatment resistance

  This study is looking at a protein called SYNCRIP to understand why some prostate cancers stop responding to hormone treatments, with the hope of finding new ways to help patients with advanced prostate cancer get better results from their therapies.

  NIH research Yale University · New Haven, United States · NIH-11221969

• Targeted therapy for myeloid blood cancers with splicing factor mutations

  This project explores whether combining two targeted drugs that block ATR and PARP can better treat adults with myeloid blood cancers that carry splicing factor mutations.

  NIH research Washington University · Saint Louis, United States · NIH-11195604

• Using time-based cancer immunograms to improve immunotherapy treatments

  This study is looking at how tracking your immune response over time can help doctors figure out the best combination of immunotherapy treatments for cancer patients, so they can receive more personalized care that works better for them.

  NIH research Institute for Systems Biology · Seattle, United States · NIH-11191812

• Timing-based immune maps to guide the order of immunotherapy and targeted cancer drugs

  This work tests whether a short course of immunotherapy given before targeted cancer drugs helps people with cancers like BRAF‑mutant melanoma respond better.

  NIH research Institute for Systems Biology · Seattle, United States · NIH-11191418

• Combining targeted drugs and immunotherapy to fight breast cancer and brain metastases

  This project combines targeted drugs with immunotherapy to help people with breast cancer, including those whose cancer has spread to the brain, respond better to treatment.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11178401

Related topics

Quick answers

How many Targeted Therapy clinical trials are recruiting right now?

14, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 3 countries. The most sites are in China (10 trials), United States (3 trials), Lebanon (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 6, Phase 1: 2, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →